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Abstract 34 
 35 
Mycobacterium tuberculosis (M.tb) is responsible for more deaths globally than any other 36 
pathogen. The only available vaccine, bacillus Calmette-Guérin (BCG), has variable efficacy 37 
throughout the world. A more effective vaccine is urgently needed. The immune response 38 
against tuberculosis relies, at least in part, on CD4+ T cells. Protective vaccines require the 39 
induction of antigen-specific CD4+ T cells via mycobacterial peptides presented by MHC 40 
class-II in infected macrophages. In order to identify mycobacterial antigens bound to MHC, 41 
we have immunoprecipitated MHC class-I and class-II complexes from THP-1 macrophages 42 
infected with BCG, purified MHC class-I and MHC class-II peptides and analysed them by 43 
liquid chromatography tandem mass spectrometry. We have successfully identified 94 44 
mycobacterial peptides presented by MHC-II and 43 presented by MHC-I, from 76 and 41 45 
antigens, respectively. These antigens were found to be highly expressed in infected 46 
macrophages. Gene ontology analysis suggests most of these antigens are associated to 47 
membranes and involved in lipid biosynthesis and transport. The sequences of selected 48 
peptides were confirmed by spectral match validation and immunogenicity evaluated by IFN-49 
gamma ELISpot against peripheral blood mononuclear cell from volunteers vaccinated with 50 
BCG, M.tb latently infected subjects or patients with tuberculosis disease. Three antigens 51 
were expressed in viral vectors, and evaluated as vaccine candidates alone or in 52 
combination in a murine aerosol M.tb challenge model. When delivered in combination, the 53 
three candidate vaccines conferred significant protection in the lungs and spleen compared 54 
with BCG alone, demonstrating proof-of-concept for this unbiased approach to identifying 55 
new candidate antigens.  56 
 57 
  58 
Introduction 59 
 60 
Mycobacterium tuberculosis (M.tb), the etiologic agent of tuberculosis (TB) is the largest 61 
cause of death by an infectious disease worldwide. M. africanum, M. canettii, M. microtti, 62 
and M. bovis, share 99.9% similarity at the nucleotide level and are grouped in the 63 
Mycobacterium tuberculosis complex (MTC), the mycobacteria causing TB disease. 64 
According to the last World Health Organization report, 1.6 million people died of TB, 65 
300,000 of which were co-infected with HIV, in 20171. With the emergence of multi-drug and 66 
extensively-drug resistant strains, as well as co-infection with HIV, new tools to control this 67 
epidemic are urgently required. The currently available vaccine against TB is a live 68 
attenuated form of Mycobacterium bovis, strain bacillus Calmette-Guérin (BCG), which has 69 
variable efficacy throughout the world2. The immune response against TB relies on CD4+ T 70 
cells, and to some extent to CD8+ T cells3, therefore protective vaccines require the induction 71 
of antigen-specific T cells through peptides presented by MHC-II and MHC-I, respectively, in 72 
infected macrophages. The identification of MTC antigens presented by MHC molecules in 73 
infected macrophages will facilitate vaccine development to boost the protective efficacy 74 
induced by BCG vaccination.  75 
 76 
Even though CD4+ and CD8+ T cells can secrete IFN-gamma (IFNγ) upon recognition of 77 
antigen, the lack of stringent immunological markers that serve as correlates of protection 78 
makes it difficult to predict whether the immune response induced by a vaccine will result in 79 
protective efficacy4. Currently there are more than a dozen vaccine candidates in different 80 
stages of clinical trials including sub-unit vaccines delivered by viral vectors, proteins in 81 
adjuvant, killed mycobacterial whole cell or extracts, recombinant BCG expressing M.tb 82 
genes, attenuated M.tb strains and BCG revaccination strategies5. Although a multitude of 83 
platforms are currently being explored for the delivery of antigens designed to replace or 84 
boost BCG, current subunit vaccines only use a limited selection of antigens6.  85 
 86 
Recent advances in immunopeptidomics based on improvements in mass spectrometry 87 
instrumentation and data analysis have led to an unprecedented improvement in sensitivity. 88 
It is now possible to precisely identify peptide sequences, bound to MHC molecules, at the 89 
femto molar scale7,8. This technology allowed the identification of epitopes presented by 90 
conventional HLA class-I molecules in ovarian cancer9, influenza10, hepatitis C11, HIV12, and 91 
TB13. Unconventional class-I, HLA-E bound peptides have been identified in cells infected 92 
with M.tb14. Leishmania HLA class-II bound peptides have been also identified, and vaccines 93 
developed based on these antigens15. Immunopeptidomics studies have attempted to 94 
decipher the immunopeptidome of mycobacteria-infected cells. Only a handful of MHC-I 95 
peptides have been described thus far13 and MHC-II peptides have not been yet identified. 96 
The identification of new vaccine antigen candidates designed to boost BCG has been 97 
limited by inherent difficulties of culturing mycobacteria and by the paucity of antigens 98 
identified so far using conventional methods. Moreover, the ability of pathogenic 99 
mycobacteria to downregulate antigen processing and presentation limits the ability to 100 
identify peptides presented by MHC molecules.  101 
 102 
Here we have used immunopeptidomic based identification of peptides presented by MHC-I 103 
and MHC-II in macrophages infected with M. bovis BCG, applying an immunopeptidomics 104 
pipeline for peptide identification by mass spectrometry and bioinformatics8 (Supplementary 105 
fig. 1). THP-1 cells were selected for this study because these are the most well-106 
characterized human macrophage cell line with a defined HLA generic genotype HLA-107 
A*02:01, HLA-B*15:11, HLA-B*15:15, HLA-C*03:03, HLA-DRB1*01:01, HLA-DRB1*15:01, 108 
HLA-DRB5*01:01, HLA-DQB1*06:02, HLA-DQB1*05:01, HLA-DPB1*04:02 and HLA-109 
DQP1*02:01 (Supplementary table 1 for allelic details), which is required for peptide binding 110 
prediction analysis once peptides have been identified. To overcome the ability of 111 
pathogenic mycobacteria to downregulate antigen processing and presentation, we 112 
stimulated cells with a cytokine mix to induce higher MHC class-II presentation, 113 
immunoprecipitated both MHC-I and MHC-II-peptide bound complexes and analysed by 114 
mass spectrometry, leading to the identification of mycobacterial peptides presented by both 115 
MHC-I and MHC-II. We have successfully identified 94 mycobacterial peptides presented by 116 
MHC-II and 43 presented by MHC-I, from 76 and 41 antigens, respectively. We have 117 
mapped the gene expression of BCG in infected macrophages and correlated the 118 
expression of the antigens identified with the global gene expression pattern in vivo. Finally, 119 
three antigens were selected, expressed in viral vectors and evaluated as vaccine 120 
candidates in a murine aerosol M.tb challenge experiment. The three candidate antigens, 121 
when delivered as viral vectors to boost previous BCG vaccination, conferred significant 122 
protection in the lungs and spleen of mice when administered in combination compared to 123 
BCG alone. This demonstrates proof-of-concept for this unbiased approach to identify new 124 
candidate antigens required for TB vaccine development. 125 
 126 
Results 127 
 128 
Immunopetidomics pipeline can be used to identify BCG-derived peptides presented 129 
by MHC molecules 130 
 131 
To maximise identification of BCG peptides presented by THP-1 cell MHC molecules, a 132 
range of conditions were performed across four infection experiments (Table 1). In all 133 
experiments, THP-1 cells were differentiated into macrophages and infected with BCG-GFP. 134 
The two first experiments consisted of 2.5 x 108 cells infected with BCG-GFP, macrophages 135 
were harvested at 1 and 7 days post-infection. In the first experiment an immunoprecipitation 136 
against MHC-I was performed while in the second experiment both MHC-II and MHC-I 137 
immunoprecipitations were conducted (Table 1).  138 
 139 
Pathogenic mycobacteria are known to downregulate antigen presentation16 at the gene 140 
expression level17, at the antigen processing level17,18 and at the antigen presentation level18, 141 
therefore limiting our ability to identify peptides. To overcome this, we developed a cytokine 142 
cocktail to improve the expression of MHC-II molecules at the surface of infected 143 
macrophages. Interleukin-10 (IL10) is secreted by macrophages infected with pathogenic 144 
mycobacteria18 and likely acts as an anti-inflammatory molecule reducing antigen processing 145 
and presentation. IFNγ has been shown to improve gene expression of MHC-II genes in 146 
infected THP-1 cells17. TNFα is important in the control of TB through diverse mechanisms 147 
including macrophage activation and granuloma formation19. We tested the effect of IFNγ, 148 
TNFα and anti-IL10 antibodies, alone or in combination to enhance MHC-II presentation in 149 
macrophages infected with BCG, and we were able to improve MHC-II but not MHC-I 150 
presentation (Supplementary fig. 2b and 2c). We observed that IFNγ  alone was able to 151 
induce higher expression of HLA-DR but combining with other cytokines did not produce a 152 
synergistic effect. Furthermore, as live mycobacteria are known to actively block antigen 153 
processing and presentation17,18 we also treated macrophages with heat-killed BCG-GFP 154 
(HK BCG). For the third and fourth experiments, we prepared six samples, three of which 155 
were stimulated with cytokine cocktail containing IFNγ to improve MHC-II expression and 156 
anti-IL10 to prevent the reduced antigen processing and presentation caused by 157 
mycobacterial infection, and three of which were left untreated. The three samples in each of 158 
these groups were then infected with live BCG-GFP, treated with HK-BCG or left uninfected. 159 
In the third experiment each sample was composed of 5 x 107 cells while in the fourth 160 
experiment each sample contained 5 x 108 cells. The rate of infection in all experiments 161 
ranged between 21% and 40% (Table 1 and Supplementary fig. 2a).  162 
 163 
Mycobacterial peptides are presented by MHC-I and MHC-II in infected macrophages   164 
 165 
Following mass spectrometric analysis of each sample, peptide spectra were analysed using 166 
Peaks (Bioinformatics Solutions). The false discovery rate (FDR) of peptide identifications 167 
was controlled using in-build simultaneous interrogation of the spectra through a decoy 168 
database fused to the target sequence database20. Each spectrum was assigned a Peaks 169 
score reflecting the confidence of the sequence interpretation. We applied a Peaks score 170 
cut-off of 15 to all samples, resulting in an average FDR of 1.65% for MHC-I, and 10.37% for 171 
MHC-II peptides. We identified a total number of 23,976 unique MHC-I and 17,765 unique 172 
MHC-II peptides. From these, 23,894 MHC-I human, 43 MHC-I BCG, 17,599 MHC-II human 173 
and 94 MHC-II BCG peptides (Fig. 1a and 1d).  174 
 175 
The MHC-I peptides showed a typical distribution of amino acid length of all human peptides 176 
identified, with the predominant 9-mer peak consisting of 55.98% of all MHC-I peptides (Fig. 177 
1b). The distribution of the MHC-II peptides revealed an enrichment of peptides ranging from 178 
12 to 18 amino acids long (Fig. 1b). Interestingly, a 9-mer peak can be observed within the 179 
MHC-II peptides, reflecting a potential non-specific co-precipitation of MHC-I peptides with 180 
MHC-II peptides21 (Fig. 1b). BCG-derived peptides were further selected based on their 181 
amino acid length. From a total of 82 MHC-I and 166 MHC-II BCG unique peptides, all MHC-182 
I BCG peptides were 8 to 15 amino acids and all MHC-II BCG peptides were 8 to 25 amino 183 
acids in length, (Fig. 1d). False positive sequences were excluded and 59 MHC-I and 105 184 
MHC-II BCG peptide sequences were further analysed (Fig. 1d). These sequences were 185 
further Blast analysed using the DeBosT script developed for this study. Moreover, the 186 
amino acids leucine (L) and isoleucine (I) are isomers, which are indistinguishable from each 187 
other in our mass spectrometry protocol. All peptides were blasted for all possible 188 
combinations of I and L, and when a combination matched a human peptide, the sequence 189 
was excluded. Applying these four data analysis criteria, we have identified 43 BCG MHC-I 190 
and 94 BCG MHC-II peptides (Fig. 1d).  191 
 192 
Forty-one MHC-I and 76 MHC-II BCG antigens were identified from the peptide sequences. 193 
Interestingly, 5 BCG antigens were common to both MHC-I and MHC-II (Fig. 1e and Table 194 
2). The peptides from the common antigens identified in MHC-II had an amino acid length 195 
ranging from 9 to 13, suggesting these could be MHC-I peptides that co-precipitated 196 
unspecifically with the MHC-II immunoprecipitation, rather than being the product of antigens 197 
presented by both MHC-I and MHC-II. 198 
 199 
All peptides identified were analysed through netMHCpan 4.022 and netMHCpanII 3.223, the 200 
reference algorithms for both MHC-I and MHC-II peptide prediction, respectively. The best 201 
match HLA binding allele and the best match score were identified and plotted for all human 202 
peptides across all samples. MHC-I peptides were more abundant that MHC-II peptides. 203 
Most MHC-I peptides were strong binders whereas most MHC-II peptides were weak 204 
binders (Fig. 1c).  205 
 206 
After additional analysis of location, function and intracellular expression level, new 207 
candidates were selected based on the highest expression levels, IFNγ-ELISpot responses 208 
and Spectral Match Validation, for further analysis as proof-of-concept. From the list of BCG 209 
antigens identified (Table 2, Supplementary table 2 and 3), three were selected for 210 
evaluation as vaccine candidates (Fig. 1f). The peptide BCG_3870c4-12 LAASLLSRV from the 211 
Galactofuranosyl transferase BCG_3870c has 100% identity to Galactofuranosyltransferase 212 
glfT2 from M.tb (Rv3808c) and was identified in two samples of the first experiment, as a 213 
MHC-I bound peptide.  214 
 215 
The fatty acid synthase (fas), was identified associated to both MHC-I and MHC-II 216 
molecules. The peptide fas2248-2257 ADLVVIVGGA was identified associated to MHC-I in the 217 
second experiment. The peptide fas57-65 GIETELATL was found associated to MHC-I in the 218 
sample NOCYT LIVEBCG from the third experiment, and the peptide fas241-249 TPEQLSRFE 219 
was found associated to MCH-II in the same sample (Supplementary tables 2 and 3).  220 
 221 
The peptide from Ag85A, fbpA44-51 FSRPGLPV, was found associated to MHC-I in the sample 222 
CYT HKBCG from the third experiment and samples CYT HKBCG A and B from the fourth 223 
experiment. Remarkably, this peptide is also present in Ag85B (fbpB41-48 FSRPGLPV) and 224 
Ag85C (fbpC47-54 FSRPGLPV). Viral vectors expressing Ag85A have been shown to improve 225 
the protective efficacy of BCG24. For these reasons, this antigen was selected for vaccine 226 
production (Fig. 1f). The iniB and PPE15 antigens were selected because they have been 227 
described previously as presented by MHC-I molecules3,13.  228 
 229 
Antigens presented by MHC-I and MHC-II are highly expressed in infected cells 230 
 231 
To verify whether the antigens identified were expressed in macrophages infected by BCG, 232 
we performed RNA-seq on THP-1 cells infected with BCG, 1 day post-infection. Proteins 233 
identified from peptides presented by MHC-I and MHC-II were plotted against normalized 234 
expression levels of all BCG genes (Fig. 2a and c). Antigens presented by MHC-I were 235 
highly expressed compared to all BCG genes (p=0.00019) (Fig. 2b). MHC-II antigens were 236 
also highly expressed (p=0.00061) although to a lesser extent (Fig. 2d). The most highly 237 
expressed gene presented by MHC-I was fas, followed by BCG_3870c (glfT2) and by all 238 
three Ag85-complex genes (fbpABC) and others. The highest expressed gene presented by 239 
MHC-II was pks2, followed by mas, fadD26, pks3 and PPE55a. 240 
 241 
Antigens presented by MHC-I and MHC-II are mostly associated with membranes and 242 
involved in lipid metabolism 243 
 244 
To understand the predicted biological function and the cellular location of each antigen, we 245 
mapped the gene ontology of each antigen (Fig. 2e to j). Despite 37% of the antigens having 246 
unknown biological functions, 47% having unknown biological processes, and 60% having 247 
unknown subcellular locations, the antigens identified on MHC-I cluster mostly in the process 248 
of transmembrane transport (Fig. 2e), with transferase activity functions (Fig. 2f) located at 249 
the membrane (Fig. 2g). The antigens identified on MHC-II cluster mostly in oxidation-250 
reduction processes and functions (Fig. 2h and i), and were strongly associated to a 251 
membrane location (Fig. 2j). Most antigens, with known functions, identified on both MHC-I 252 
and MHC-II were associated with the biosynthesis and transport of lipids and were located at 253 
the cell membrane, however, there is no significant over or under representation of 254 
membrane- or cell wall-associated proteins relatively to the entire BCG proteome.  255 
 256 
Peptide sequences identified by mass spectrometry are confirmed by spectral match 257 
validation 258 
 259 
Based on the FDR, the PSMs identified using Peaks have a low probability of being false 260 
positives. However, to confirm that the peptide sequences were assigned correctly, a 261 
spectral match validation experiment was performed. Synthetic peptides were produced and 262 
compared to a selection of PSMs obtained from our experiments, herein referred to as 263 
biological peptides. Synthetic peptides were run in the same experimental conditions as 264 
biological peptides. The mass over charge [m/z] for each peptide, the charge state, the 265 
intensity and distribution of each peak within each peptide sequences, as well as the peptide 266 
specific retention time (RT) on the liquid chromatography were compared between synthetic 267 
and biological peptides and the sequences matched (Supplementary fig. 3).  268 
 269 
Single peptides identified by immunopeptidomics are recognized by PBMCs from 270 
HLA-matched BCG-vaccinated subjects 271 
 272 
To evaluate whether the peptides identified could be recognized by BCG-vaccinated 273 
volunteers, IFNγ-ELISpots were performed on peripheral blood mononuclear cells (PBMCs) 274 
collected in previous clinical trials. Peptide responses were evaluated in healthy volunteers 275 
who had received BCG vaccination, subjects with latent M.tb infection and patients with 276 
active TB disease. The HLA types of the volunteers were known (Supplementary table 4), 277 
allowing us to match a subset to the HLA type of the THP-1 cells (Supplementary table 1).  278 
 279 
The Ag85A peptide, fbpA44-51 FSRPGLPV, showed the highest response in the BCG-280 
vaccinated HLA-matched group (mean=11.34 spots per million PBMCs). There was a 281 
statistically significant difference between the responses in the BCG-vaccinated HLA-282 
matched group, compared with the responses in the M.tb infected HLA-matched group 283 
(p=0.048), the non-HLA matched group (p= 0.0143) and the TB disease group (p=0.0079) 284 
(Fig. 3a). 285 
 286 
The glfT2 peptide, BCG_3870c4-12 LAASLLSRV, showed the highest response in the M.tb 287 
infected HLA-matched group (mean=25.23 spots per million PBMCs). However, the 288 
responses in the BCG-vaccinated HLA-matched group were significantly different from the 289 
responses in the M.tb infected non-HLA matched (p=0.041) and active TB groups 290 
(p=0.0079). The responses in the M.tb infected HLA-matched group were different from 291 
those in the active TB group (p=0.0189) (Fig. 3b). Responses to the fatty acid synthase 292 
peptide, fas57-65 GIETELATL, the isoniazid inducible gene protein iniC peptide, iniC191-200 293 
QIGGLVGGSV, and the 60 kDa chaperonin 2 peptide, groL261-75 LEDPYEKIGAELVKE were 294 
not different between groups (Fig. 3c, d and e respectively). Responses to the pool of 295 
peptides composed of the five previous peptides, mmpL12396-403 AGCTLLIR and atpA333-340 296 
KANDISAY, were significantly higher in the M.tb infected HLA-matched compared to the 297 
BCG vaccinated non-HLA matched (Fig. 3f). Therefore, although the IFNγ-ELISpot 298 
responses were generally low for all groups, significant differences were observed for 299 
several individual peptides and the peptide pool in BCG-vaccinated individuals.  300 
 301 
Selected antigens conferred significant protection when delivered in combination 302 
 303 
Peptides identified by mass spectrometry (Fig. 1), originating from mycobacterial antigens 304 
that are expressed in infected macrophages (Fig. 2), validated by spectral match validation 305 
(Supplementary fig. 3) and ELISpot (Fig. 3) were selected to be evaluated as vaccine 306 
candidates. To determine whether these antigens could offer protective efficacy against TB 307 
disease, we produced viral vectors expressing each antigen (Supplementary fig. 4). These 308 
antigens were evaluated as vaccine candidates alone or in combination in a murine aerosol 309 
M.tb challenge experiment.  310 
 311 
The BCM vaccination schedule consists on a BCG vaccination (B), followed by a boost of a 312 
replication-deficient chimpanzee adenovirus, ChAdOx1 (C) and a second boost of 313 
replication-deficient modified Vaccinia virus Ankara, MVA (M), expressing the antigen of 314 
interest24. Two challenge experiments were performed. In the first experiment viral vectors 315 
expressing Ag85A were used as a positive control (Fig. 4b and c). Mice vaccinated with 316 
BCM regimens with individual antigens showed a significant lower median CFU compared to 317 
BCG vaccination alone in the lung, using Mann-Whitney U test (MW): BCG versus BCM-318 
glfT2 (p=0.0207), BCG versus BCM-fas (p=0.0281) and BCG versus BCM-Ag85A 319 
(p=0.0207), although not significantly different for BCG versus BCM-iniB or when using 320 
Kruskal-Wallis followed by Dunn’s multiple comparison tests (KW-DM), in lung and spleen 321 
(Fig. 4b and c).   322 
 323 
In the second experiment, viral vectors expressing PPE15, recently described as a new 324 
protective antigen against TB25, were used as a positive control. The BCM regimen with 325 
BCM-PPE15 showed a significant lower median CFU compared to BCG vaccination alone 326 
(MW p=0.0148) in the spleen but not in the lung and not with KW-DM. The other individual 327 
antigens were not significantly different compared to BCG vaccination alone both with MW or 328 
KW-DM. However, when combining the three antigens glfT2, iniB and fas (GIF), even at 2.5 329 
fold lower dose per antigen, the efficacy of this regimen was significantly higher in the lung, 330 
compared to BCG alone (MW p=0.0095, KW-DM p=0.0144) (Fig. 4d), and in the spleen (MW 331 
p=0.0148, KW-DM p=0.0141) (Fig. 4e). When combining GIF with PPE15 and Ag85A 332 
(GIFPA) at the same dose, the significance is maintained in the lung, compared to BCG 333 
vaccination alone, (MW p=0.0042, KW-DM p=0.0261) (Fig. 4d), and in the spleen (MW 334 
p=0.0019, KW-DM p=0.0081) (Fig.4e). Therefore, new pooled antigens identified by 335 
immunopeptidomics protected mice from M.tb disease in a murine challenge model. 336 
 337 
Discussion 338 
 339 
We have identified MHC-I and MHC-II bound peptides in macrophages infected with M. 340 
bovis BCG. We have successfully identified 94 mycobacterial peptides presented by MHC-II 341 
and 43 presented by MHC-I, from 76 and 41 antigens, respectively. Three new antigens 342 
were expressed alongside others in viral vectors, and evaluated as vaccine candidates alone 343 
or in combination in a murine aerosol M.tb challenge model. When delivered in combination, 344 
these antigens conferred significant protection in the lungs and spleen compared with BCG 345 
vaccination alone. This demonstrates proof-of-concept for an unbiased approach to discover 346 
new candidate antigens.  347 
 348 
The new vaccine antigens are glfT2, fas and iniB. The galactofuranosyltransferase, glfT2, 349 
identified in this study as BCG_3870c, contains 637 amino acids and is 100% identical to the 350 
glfT2 of M.tb (Rv3808c). This is a bifunctional transferase required for the biosynthesis of 351 
M.tb arabinogalactan26, part of the mycolyl–arabinogalactan–peptidoglycan (mAGP) complex 352 
of the cell wall which is essential for mycobacterial viability27 and its crystal structure has 353 
been resolved28. Interestingly, this antigen was listed in the first report of peptide 354 
identification from M.tb using mass spectrometry13.  355 
 356 
The fatty acid synthase, fas in M. bovis BCG (Rv2524c in M.tb), is a very large protein 357 
containing 3,069 amino acids in both species, with 99.97% identity. Fas, also known as FAS-358 
I, is a eukaryotic‐like enzyme that is involved in fatty acid biosynthesis in mycobacteria29-31. 359 
FAS-I is an essential multi-functional enzymatic complex, that catalyses the de novo 360 
synthesis of fatty acids from acetyl‐CoA, contributing to the virulence of M.tb by elongating 361 
fatty acids30. The crystal structure of this enzyme has been resolved30. In fact, several 362 
enzymes of the polyketide synthase family were identified in this study (pks12 presented by 363 
MHC-I, pks2 and pks8 presented by MHC-II), thus suggesting that these may also be 364 
relevant targets for vaccine development. Moreover, the transfer of mycolic acids produced 365 
by the FAS-I and FAS-II complexes to arabinogalactan synthesized partially by glfT2 is 366 
catalysed by the Antigen 85 complex31,32. In this study, the vaccine GIFPA containing a 367 
combination of antigens that included fas, glfT2, Ag85A and PPE15 and iniB, showed the 368 
highest efficacy.  369 
 370 
The isoniazid inducible gene protein iniB, is a 479 amino acid long protein identified for the 371 
first time by mass spectrometry in 200213. In the same paper the authors described the 372 
identification of peptides from hsp65 (groEL2) and glfT2 (Rv3808c), both also identified in 373 
our study. That study identified three nested sequences of the isoniazid inducible gene 374 
protein iniB from M.tb (Rv0341) through pan-HLA class-I immunoprecipitation (Rv034133-375 
42,GLIDIAPHQI; Rv034133-44, GLIDIAPHQISS; Rv034133-45, GLIDIAPHQISSV)13. The same 376 
nested sequence was identified 15 years later as an M.tb peptide associated with soluble 377 
HLA-E (Rv034133-47, GLIDIAPHQISSVAA)14. We have identified Isoniazid inducible gene 378 
protein iniC peptide sequence iniC191-200 QIGGLVGGSV in two experiments (Supplementary 379 
table 2). Moreover the Rv0341 (iniB) protein shares 27.96% identity with iniC, and the 380 
sequence iniC191-200 has 5 amino acids in common with Rv0341. Although we have not 381 
identified peptides from iniB, we found peptides from iniC, suggesting that this family 382 
(encoded in an iniBAC operon) may be co-expressed. These genes were highly expressed 383 
by MTC bacteria in infected macrophages33. Even though the antigen alone did not confer 384 
protection compared to BCG, significance was obtained when in combination with other 385 
antigens (Fig. 4).  386 
 387 
Most antigens presented by MHC-I and MHC-II were associated with the biosynthesis and 388 
transport of lipids and were located at the cell membrane. These include but were not limited 389 
to the mycobacterial membrane protein Large (mmpL) family, which we have identified 390 
mmpL12, mmpL14 and mmpL3, presented by MHC-I molecules. The mmpLs are 391 
transporters involved in the export of lipids across the cell wall, and have been implicated in 392 
drug resistance and are drug targets34,35. These proteins are conserved across mycobacteria 393 
and most of their functions are unknown34. MmpL3, which is essential for viability36, has 394 
received much interest as a drug target35. Its crystal structure has been recently resolved35, it 395 
is involved in the transport of trehalose monomycolate (TMM) across the cell wall, a 396 
precursor of trehalose dimycolate TDM, which is a major glycolipid involved in mycobacterial 397 
virulence37 by activating matrix metalloproteinases38. TMM is exported from the plasma 398 
membrane to the periplasmic space by mmpL3 and sent to the Ag85 complex that 399 
metabolises TMM into TDM34. MmpL3 has also been implicated in the import of heme 34.  400 
 401 
In this study we identified nested peptides presented by MHC-II, originating from Heparin-402 
binding hemagglutinin, hbhA in M. bovis BCG, which is 199 amino acid long, and has 100% 403 
identity to Rv0475 of M.tb H37Rv and is an important virulence factor of M.tb39. This antigen 404 
is a well-known immunogen and vaccine candidate40,41 that is able to induce multifunctional 405 
CD4+ T cells in HIV and non-HIV co-infected TB patients42. It induces a subset of CD4+ T 406 
cells with cytolytic functions41, and it is a known adhesin43 that is involved in bacterial 407 
agglutination and has been implicated in the dissemination of M.tb44. It has been found in 408 
different intracellular locations, participates in the formation of lipid inclusions and can bind 409 
charged lipids specifically to 4,5-phosphatidylinositol diphosphate45.  410 
 411 
We also have also identified a series of nested peptides presented by MHC-II originating 412 
from GroL2. The GroL2 of M. bovis BCG (also known as 60 kDa chaperonin 2, protein 413 
CPN60-2, 65 kDa antigen, heat shock protein 65, cell wall protein A and antigen A46) is a 414 
well-known human47 and veterinarian48 vaccine candidate against TB as well as against 415 
head and neck cancer49, that has been widely studied as a DNA vaccine in mice50. GroL2 416 
has 100% identity to the well-known GroEL2 of M.tb, 94.83% identity with GroEL of 417 
M.leprae, 93.37% identity with GroEL of the saprophyte M. smegmatis and 47.16% identity 418 
with human heat shock proteins. This 540 amino acid long antigen, activates dendritic cells51 419 
and macrophages through the TLR4/NF-κB signalling pathway52 and induces strong CD4+ T 420 
cell responses47. Due to high conservation between human and mycobacterial heat shock 421 
proteins, peptides presented by MHC molecules might induce cross-reactivity of T cells that 422 
would break tolerance that could lead to autoimmunity53. Therefore, GroL2 epitopes should 423 
be carefully considered when designing vaccines against TB, even though they are 424 
presented by MHC-II molecules in infected macrophages.  425 
 426 
The PE/PPE family were identified for the first time in the M.tb genome sequence29 and have 427 
gathered much interest from the community as potential vaccine candidates25. Here we used 428 
PPE15 (Rv1039c), as a control antigen, alone and in combination with other antigens. Even 429 
though PPE15 alone conferred protection compared to BCG in the spleen but not in the 430 
lung, it has been shown to be protective in previous studies25 and in our study was able to 431 
confer significant protection when used in combination with other antigens (Fig. 4). We 432 
observed significant protective efficacy when the new antigens were combined, suggesting 433 
immunological synergy between these antigens. The immunogenicity of these antigens 434 
alone or in combination, the mechanisms by which protective efficacy is improved, and 435 
immune correlates of protection which are still largely unknown, remains to be addressed in 436 
future studies. 437 
 438 
In our study we identified PE/PPE family members, such as the PPE50 and PE-PGRS50. 439 
Interestingly, peptide pools from PPE50/PPE51 induced significant numbers of IFNγ 440 
secreting T cells by ELISpot in PBMCs from M.tb infected individuals compared to patients 441 
with TB disease and PE-PGRS50 induced significant numbers of IFNγ secreting T cells from 442 
patients with TB disease compared to M.tb latently infected individuals3. The implication of 443 
the MHC presentation of peptides from PPE50 and PE-PGRS50 on the outcome of M.tb 444 
infection or TB disease are yet to be determined. Many other relevant genes were also 445 
identified in this study, which could also be of interest as new vaccine candidates, including 446 
ppsD, sseB, carB, groS and rplV, among others. 447 
 448 
The pool of peptides used in IFNγ-ELISpots showed a difference between responses in BCG 449 
vaccinated non-HLA matched subjects and HLA-matched volunteers with latent M.tb 450 
infection. In fact, a higher response of the peptide pool in M.tb latently infected individuals 451 
may reflect the contribution of the BCG_3870c4-12 LAASLLSRV peptide, as it showed a 452 
significantly higher response in PBMC from HLA-matched latently infected individuals 453 
compared to patients with TB disease. Also, the groL261-75 LEDPYEKIGAELVKE peptide 454 
showed a high response in PBMC from HLA-matched, latently infected individuals. These 455 
responses with the single peptides may result in a higher overall response in HLA-matched, 456 
latently infected individuals against a pool of peptides. The contribution of the groL2 and 457 
BCG_3870 peptides may have hindered the effect of the other individual peptides on the 458 
pool. Interestingly, the single peptides fbpA44-51 FSRPGLPV and BCG_3870c4-12 LAASLLSRV, 459 
showed a significantly higher response in PBMC from HLA-matched, BCG-vaccinated 460 
volunteers compared to non HLA-matched, M.tb infected subjects and subjects with TB 461 
disease, suggesting potential recognition of these epitopes by BCG-vaccinated individuals.  462 
 463 
We propose a new combination of techniques based in immunopeptidomics to discover, 464 
analyse and test new vaccine candidates against tuberculosis. We have identified multiple 465 
new MHC class-I and class-II antigens, tested three new antigens alone or in combination to 466 
show efficacy, driving forward the discovery of new vaccines that are desperately needed to 467 
control this global pandemic. 468 
 469 
Methods 470 
 471 
Cells and bacteria 472 
 473 
Human primary monocytes were obtained from leukapheresis cones from the local blood 474 
transfusion service. Human monocyte derived macrophages were produced as described 475 
previously54. PBMC were obtained from healthy UK adults aged 18-55 who participated in 476 
vaccination studies approved by the Oxfordshire Research Ethics Committee55. PBMC from 477 
BCG-vaccinated individuals were obtained from a previous clinical trial NCT00480714 478 
(TB003)55, or ongoing clinical trials: ClinicalTrials.gov Identifier NCT02380508 (TB038) and 479 
NCT02709278 (TB041). Samples from latently infected individuals were obtained from a 480 
previous clinical trial NCT00456183 (TB007)56 and samples from TB disease patients were 481 
obtained from a previous study57. Methods using samples collected from human volunteers 482 
were conducted in accordance with the ethical principles of the Declaration of Helsinki, Good 483 
Clinical Practice, and local regulatory requirements. All volunteers provided informed 484 
consent for study participation.  485 
 486 
THP-1 monocytes (ATCC TIB-202) were induced into phagocytic macrophage-like cells by 487 
stimulation with 20 nM Phorbol 12-Myristate Acetate (PMA, Sigma-Aldrich, UK), overnight. 488 
Cytokine treatments included 50 ng/mL IFNγ, 50 ng/mL TNFα (both from Immuno Tools, 489 
Germany) and 1 μg/mL anti-IL10, (clone JES3-9D7, BD Biosciences, UK) post PMA 490 
activation. HLA genotype of the cells and detailed allelic information is shown in 491 
Supplementary table1.  492 
HeLa cells (ATCC CCL-2.1) were used for ChAdOx1 and MVA infections to monitor the 493 
expression of each antigen, by western blot. 494 
 495 
For in vitro infection, BCG Montreal (ATCC 35735)58, containing pEGFP cloned under the 496 
control of mycobacterial 19 kDa promoter59 was kindly provided by Dr Rajko Reljic from St 497 
George's University of London, whereinafter designated as BCG-GFP. BCG-GFP was grown 498 
in medium containing Middlebrook's 7H9 broth (BD Biosciences, UK), supplemented with 499 
10% OADC enrichment (BD Biosciences, UK), 0.2% glycerol and 0.05% tyloxapol at 37 ºC, 500 
in aerobic conditions, on a shaker at 200 rpm54. BCG-GFP was used to determine the rate of 501 
infection of the THP-1 infection experiments, by flow cytometry. 502 
 503 
For BCG mouse vaccinations, BCG Pasteur (ATCC 35734) was grown in 7H9 broth (BD 504 
Biosciences, UK) containing 0.05% Tween 80 (Sigma-Aldrich, UK) and 10% ADC (Sigma-505 
Aldrich, UK).  506 
 507 
For M.tb mouse challenges, M.tb Erdman K01 (TMC107) was obtained from BEI resources, 508 
Manassas, USA.  509 
 510 
Macrophage infection 511 
 512 
Bacterial cultures in exponential growth phase were centrifuged at 2851 xg for 10 minutes, 513 
washed in phosphate-buffered saline (PBS), and resuspended in the desired culture medium 514 
without antibiotics. To dismantle bacterial clumps, the bacterial suspension was subjected to 515 
15 min of ultrasonic bath. Residual clumps were removed by 1 min centrifugation at 931 xg. 516 
Single-cell suspension was verified by fluorescence microscopy. THP-1 cells were infected 517 
with BCG-GFP, alive or heat-killed, at a Multiplicity of Infection (MOI) of 10, with or without 518 
pre-treatment with IFNγ and anti-IL10 (Supplementary fig. 1a and table 1) for 4 h at 37 ºC 519 
with 5% CO2. Following internalization, cells were washed with PBS and resuspended in 520 
appropriate culture medium without antibiotics54. One or 7 days post-infection, cells were 521 
harvested, lysed and total proteins collected (Supplementary fig. 1a). 522 
 523 
Flow cytometry and Western blot 524 
 525 
Macrophages were harvested with a cell scraper and fixed with 4% paraformaldehyde for 20 526 
minutes, followed by cell staining with antibodies specific for human HLA-ABC, dilution 1:100 527 
(clone W6/32, BioLegend, UK, Cat. No. 311418) or HLA-DR dilution 1:25 (clone L243, 528 
BioLegend UK, Cat. No. 307606), for 30 min. Determination of the rate of infection was 529 
performed based on the percentage of GFP positive cells, on fixed cells 24 h post-infection, 530 
after washing several times with PBS to remove extracellular bacteria. Samples were run on 531 
an LSR II flow cytometer and the data analysed using FlowJo (TreeStar Inc, Ashland, USA).  532 
 533 
HeLa cells infected with ChAdOx1 and MVA cloned with each selected antigen were used 534 
detect antigen expression by western blot, using the iBind Western System (Invitrogen, UK). 535 
Antigens were detected with a primary Histidine Tag antibody, diluted 1:1000 BioRad, Cat. 536 
No. MCA1396, clone AD1.1.10, followed by a secondary polyclonal antibody, Goat Anti-537 
Mouse IgG Fc (Alkaline Phosphatase), dilution 1:1000 (Abcam, UK, Cat. No. ab98710). 538 
 539 
Isolation of HLA-bound peptides 540 
 541 
An equivalent of 1x108 cells were lysed in 1 ml lysis buffer (0.5% Igepal, 150 mM NaCl, 50 542 
mM Tris, pH 8.0, supplemented with complete™ protease inhibitor cocktail (Roche)). HLA 543 
complexes were immunoprecipitated using 1 mg monoclonal antibody L243 against HLA-DR 544 
per 1x108 cells followed by 1 mg monoclonal antibody W6/32 against pan-HLA class-I 545 
complexes (GE healthcare) cross-linked to Protein A Sepharose beads using dimethyl 546 
pimelimidate (DMP, Sigma) (Supplementary fig. 1b). Lysates were incubated overnight with 547 
L243 beads followed by W6/32 beads. Beads were subsequently washed with 10 column 548 
volumes of 2x150 mM NaCl in 50 mM Tris, 1x450 mM NaCl in 50 mM Tris and 50 mM Tris 549 
buffer without salt. Peptides bound to the HLA groove were released with 5 mL 10% acetic 550 
acid. The HLA-bound peptides were further purified by HPLC (Ultimate 3000, Thermo 551 
Scientific) on a ProSwift RP-1S 4.6 x 50 mm column (Thermo Scientific) by applying a linear 552 
gradient of 2-35% (v/v) acetonitrile in 0.1% (v/v) formic acid in water over 10 min 553 
(Supplementary fig. 1c). Alternating fractions that did not contain larger complex components 554 
were pooled into two final fractions, concentrated and kept at -80°C prior to MS analysis.  555 
 556 
Mass spectrometry and data analysis  557 
 558 
Peptides were suspended in 20 μl buffer A (1% acetonitrile, 0.1% TFA in water) and 559 
analyzed by nUPLC-MS/MS using an Ultimate 3000 RSLCnano System coupled with an 560 
Orbitrap Fusion Lumos Tribrid mass spectrometer (Thermo Scientific) or a TripleTOF 5600 561 
(Sciex) (first experiment only)12. 9 μl of each sample was injected and trapped onto a 3 μm 562 
particle size 0.075 mm x 150 mm Acclaim PepMap RSLC column at 8 μl/min flowrate. 563 
Peptide separation was performed at 40ºC by applying a 1 or 2h linear gradient of 3-25% 564 
(v/v) acetonitrile in 0.1% (v/v) formic acid, 5% DMSO in water at a flow rate of 250 μl/min on 565 
a 2 μm particle size, 75 μm x 50 cm Acclaim PepMap RSLC column. For HLA class II 566 
samples, a linear gradient of 5-30% (v/v) acetonitrile was applied. Peptides were introduced 567 
to a Fusion Lumos mass spectrometer (Thermo Scientific) via an Easy-Spray source at 2000 568 
V. The ion transfer tube temperature was set to 305ºC. Measurement of precursor peptides 569 
was performed with a resolution of 120,000 for full MS (300-1500 m/z scan range) at an 570 
AGC target of 400,000. Precursor ion selection and fragmentation by high-energy collisional 571 
dissociation (HCD at 28% collision energy for charge state 2-4, 35% for charge state 1) was 572 
performed in TopSpeed mode at an isolation window of 1.2 Da for singly to quarterly 573 
charged ions at a resolution of 30,000 and an AGC target of 300,000 in the Orbitrap for a 574 
cycle duration of 2 seconds. Singly charged ions were acquired with lower priority8. 575 
 576 
MS data were analyzed with Peaks 860 (Bioinformatics Solutions) for identification of peptide 577 
sequences (Supplementary fig. 1d). Spectra were matched to all reviewed 20997 human 578 
SwissProt entries from 09/11/2017 combined with Mycobacterium bovis (strain BCG / 579 
Pasteur 1173P2) was produced based on UniProt proteomes61. The results were filtered 580 
using a score cut-off of -lg10P=15. The searches were performed with the following 581 
parameters: no enzyme specificity, no static and variable modifications, peptide tolerance: ± 582 
5ppm and fragment tolerance: ± 0.03 Da.  583 
 584 
Human sequences were disregarded from the analysis. The PSMs of mycobacterial origin 585 
obtained were analysed following a pipeline consisting of: 1) A Peaks score cut-off of 15 was 586 
applied to all samples (Fig. 1d and supplementary fig. 1e); 2) Identical BCG sequences 587 
identified in every sample or containing incorrect identification were considered false 588 
positives and were excluded (Fig. 1d); 3) A stringent Blast analysis was performed on every 589 
peptide sequence using the DeBosT script. Peptides with two or more amino acids different 590 
from human sequences were considered non-human and identified as BCG peptides 591 
(Supplementary fig. 1f). Peptides with higher netMHC rank were prioritized (Supplementary 592 
fig. 1g). All the combinations of I/L amino acids were also considered to exclude potential 593 
human sequences. MHC-I peptides were divided based on their presence in more than one 594 
sample (8) or not (35). When found in more than one sample, peptides observed in different 595 
experiments (5) were separated from peptides seen in the same experiment (3). The MHC-I 596 
peptides found in one sample (35) were divided into different peptide sequences found on 597 
the same antigen (6) or peptide sequences found in one antigen only (29). MHC-II peptides 598 
were divided following the same criteria, however, the peptides found in more than one 599 
sample included nested peptides (20) which is a common feature of HLA-bound peptides62, 600 
or found in one sample (74). When found in more than one sample and nested, peptides 601 
observed in different experiments (17) were separated from peptides seen in the same 602 
experiment (3). The MHC-II peptides found in one sample were divided into different peptide 603 
sequences found on the same antigen (6) or peptide sequences found on one antigen only 604 
(68) (Fig. 1d). Selected peptides sequences were confirmed by spectral match validation 605 
against a synthetic peptide (Supplementary fig. 1h and 3). Final lists of MHC class-I and 606 
MHC class-II peptides were generated (Supplementary tables 2 and 3, respectively).  607 
 608 
DeBosT script 609 
 610 
Blast searches (National Library of Medicine, https://blast.ncbi.nlm.nih.gov) of putative 611 
mycobacterial sequences were performed using a batch script, available upon request. 612 
Mycobacterial sequences with less than two amino acid differences compared to human 613 
sequences were excluded from downstream analysis. 614 
 615 
Synthetic peptides 616 
 617 
Synthetic peptides were synthesized by Mimotopes, UK, GeneScript, USA and Peptide 618 
Protein Research, UK. Peptides were dissolved in DMSO to 5 mM for spectral match 619 
validation and biological validations (ELISpot).  620 
 621 
Viral vector generation  622 
 623 
ChAdOx1 and MVA expressing each antigen were cloned using GeneArt Technology 624 
(ThermoFisher Scientific, UK). Four mammalian codon-optimized antigens (fasD1, fasD2, 625 
glfT2, iniB) and flanked by a Kozak consensus sequence, a tPA leader sequence, a GS 626 
linker at the 5’-end and a PK tag, Histidine tag and STOP codon at the 3’ end, were cloned 627 
into a GeneArt entry vector and then recombined into ChAdOx1 or MVA destination 628 
plasmids as previously described63,64. ChAdOx1 and MVA expressing Ag85A and PPE15 629 
were produced as previously described24,25. Construct sequences are available upon 630 
request.  631 
 632 
Mice  633 
 634 
Six to nine weeks old female CB6F1/Crl mice were purchased from Charles River, UK. All 635 
procedures were performed in accordance with the UK Animals (Scientific Procedures) Act 636 
1986 under project license number P9804B4F1 granted by the UK Home Office and 637 
received ethical approval from the Local Ethical Review Committee at the University of 638 
Oxford. Hybrid CB6F1 mice were used to include a broader MHC presentation compared to 639 
inbred parental C57BL/6 and BALB/c strains.  640 
 641 
Immunizations 642 
 643 
The vaccination regimen was composed of a BCG prime, followed by an adenovirus 644 
(ChAdOx1) initial boost and a MVA second boost, expressing each antigen to be evaluated 645 
as a new vaccine candidate. This regimen, designated as BCM, has been validated as the 646 
best method to induce protection in a mouse M.tb aerosol challenge model24,25.  647 
 648 
Groups of eight mice were vaccinated with 50 μL 4x105 CFU BCG Pasteur (ATCC 35734) 649 
intradermally (i.d.), followed by intranasal (i.n.) booster vaccination 10 weeks later, with 650 
1x108 infectious units (IU) of ChAdOx1.glfT2, ChAdOx1.fasD1 mixed with ChAdOx1.fasD2, 651 
ChAdOx1.iniB, ChAdOx1.PPE15, ChAdOx1.Ag85A alone or in combination in 50 μL, 652 
followed by intradermal vaccination 4 weeks later, with 5x106 plaque forming units (pfu) of 653 
MVA containing the same antigens in 50 μL. For vaccines containing multiple antigens, 654 
0.4x107 IU of ChAdOx1 and 2x106 pfu of MVA containing each antigen were administered.  655 
 656 
M.tb challenge experiments 657 
 658 
Four weeks after the last vaccination, mice were challenged with an M.tb aerosol four weeks 659 
after last vaccination. Aerosol challenge was performed using a Biaera AeroMP-controlled 660 
nebuliser (Biera technologies; Hagerstown, USA) contained in a Biosafety level 3 TCOL 661 
isolator as previously described24,25. Animals were loaded in nose-only restrainers and 662 
exposed to aerosolised M.tb Erdman K01 (TMC107) (BEI resources; Manassas USA), 663 
prepared at 1x106 CFU/mL in the nebuliser. The challenge protocol consisted of a 10 min 664 
run, followed by a 5 min purge, at an airflow 12 L/min, and pressure 20 psig. Mice were 665 
infected with approximately 50-100 CFU, confirmed 24 hours post- challenge in two mice per 666 
experiment.  667 
 668 
Four weeks post-challenge, lungs and spleens of mice were harvested for mycobacterial 669 
quantification. Organs were placed in reinforced homogenisation tubes (Stretton-scientific, 670 
UK) containing 1 ml of PBS and homogenised using Precellys-24 (Stretton-scientific) at 5500 671 
rpm for 20 seconds. Dilutions were prepared in PBS and plated in duplicate on modified 672 
7H11 agar plates (APHA)65. Plates were incubated at 37oC and counted five weeks later 673 
(Fig. 4). 674 
 675 
Transcriptional profiling intracellular M. bovis BCG 676 
 677 
THP-1 cells were infected at an MOI of 10:1 for 4h at 37ºC with 5% CO2. After 4h, the cells 678 
were washed with PBS and then incubated in RPMI without antibiotics for a further 20h. 679 
Mycobacterial RNA was harvested using the GTC/Trizol differential lysis method and purified 680 
using RNeasy columns (Qiagen) with DNase treatment33. Mycobacterial RNA yield and 681 
quality was assessed using the NanoDrop One Spectrophotometer (Thermo Scientific) and 682 
Agilent 4200 TapeStation (Agilent Technologies). Libraries for RNA sequencing were 683 
prepared from three (2ug total RNA) biological replicates of intracellular M. bovis BCG after 684 
rRNA depletion (Ribo-Zero, Illumina) using the NEBNext Ultra II kit (New England Biolabs), 685 
and sequenced on an Illumina NextSeq500 sequencer. Paired-end reads were mapped to 686 
the M. bovis BCG Pasteur 1173P2 genome using STAR (v2.6.0c) and normalised using 687 
Relative Log Expression (RLE) in DESeq2 (v1.20.0)66. Transcript abundance was estimated 688 
by ranking the average expression ratio for each gene relative to all genes.  689 
 690 
Ex vivo Interferon-gamma ELISpot Assay 691 
 692 
Peripheral blood mononuclear cells (PBMCs) isolated from whole blood and ELISpots were 693 
performed as previously described55. Responses to selected individual peptides or a pool of 694 
peptides, 2 µg/mL each peptide, identified in this study were assessed. Responses were 695 
corrected by subtracting the number of spots from the unstimulated cells. Results were 696 
reported as spot-forming cells (SFC) per million PBMCs.  697 
 698 
Statistical analyses  699 
 700 
Statistical analysis was performed on GraphPad Prism 8. Analysis of data sets was 701 
performed using two-tailed Mann-Whitney U test or Kruskal-Wallis followed by post-hoc 702 
tests, for multiple comparisons.  703 
 704 
Data Availability 705 
 706 
Fully annotated RNA-seq data have been deposited in ArrayExpress; accession number E-707 
MTAB-8057.  708 
The mass spectrometry data that supports the findings of this study are available at PRIDE, 709 
identifier PXD015646 (fourth experiment). Other experimental data is available from the 710 
corresponding author upon request.  711 
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Figure Legends 935 
 936 
Fig. 1 Peptide identification and selection of vaccine candidates. a Distribution of unique 937 
human peptides identified in each experiment. Distribution of unique human peptides from 938 
the four experiments combined, identified in function of length (b), and according to the 939 
netMHCpan rank (c). The best match HLA binding allele for each peptide was determined 940 
and selected. MHC-I peptides with a rank ≤ 0.5 or between 0.5 and 3.0 were considered 941 
strong or weak binders, respectively. MHC-II peptides with a rank ≤ 2 or between 2 and 10 942 
were considered strong or weak binders, respectively. The remaining peptides were 943 
excluded. The alleles identified as best binders were HLA-A*02:01, HLA-B*15:11, HLA-944 
B*15:15, HLA-C*03:03, HLA-C*03:13, HLA-DRB1*01:01, HLA-DRB1*15:01 and HLA-945 
DRB5*01:01. d Selection of unique BCG peptides from total peptides following the pipeline 946 
for identification. A Peaks score cut-off of >15 was used for the peptide identification. After 947 
applying our data analysis pipeline, peptides were selected for presence in more than 1 948 
sample (I, II). These were further selected if found in different experiments (III, IV) or if found 949 
in more than one sample but not in different experiments (V, VI). If peptides were not present 950 
in more than one sample, they were further down-selected into different peptide sequences 951 
found on the same antigen (VII, VIII) or found only once (IX, X). MHC-II peptides also 952 
presented nested sequences included in II and IV. e Total BCG antigens identified by MHC-I 953 
and MHC-II. f Table showing selected antigens for vaccine production.  954 
 955 
Fig. 2 Gene expression and gene ontology of antigens identified. Associated genes of MHC-956 
I (a) and MHC-II presented peptides (c) are highly expressed in M. bovis BCG RNA 957 
extracted after 24h infection of THP-1 cells. Normalized expression levels of M. bovis BCG 958 
genes were measured by RNA-seq. Genes encoding peptides detected on MHC-I (b) or 959 
MHC-II (d) are significantly higher expressed compared to all genes in M. bovis BCG RNA 960 
extracted after 24h infection of THP-1 cells. The lower and upper hinges correspond to the 961 
first and third quartiles (the 25th and 75th percentiles) and the centre line corresponds to the 962 
median. The upper whisker extends from the hinge to the largest value no further than 1.5 * 963 
IQR from the hinge (where IQR is the inter-quartile range). The lower whisker extends from 964 
the hinge to the smallest value at most 1.5 * IQR of the hinge. Gene ontology of identified 965 
antigens. Proteins of MHC-I and MHC-II associated peptides (Table 2) were linked to EBI 966 
QuickGO Gene ontology clusters and displayed as chord plots for the three aspects 967 
Biological Process (e, h), Molecular Function (f, i) and Cellular Component (g, j). Proteins 968 
without a GO category were labelled as Unknown. To prevent overplotting, only the first 22 969 
GO categories are shown and all lower categories as determined by enrichment p-values 970 
were labelled as “Other”. P-values were estimated using a Mann-Whitney test.  971 
 972 
Fig. 3 Peptide-specific responses of IFNγ secreting PBMCs from patient groups. ELISpots of 973 
PBMCs from 14 BCG vaccinated individuals HLA-matched (n=5), BCG vaccinated 974 
individuals non-HLA matched (n=8), latently infected individuals HLA-matched (n=7), latently 975 
infected individuals non-HLA matched (n=10 in a, b, c, d and e; n=9 in f) and tuberculosis 976 
active patients (n=5 in a, b, c, d and e; n=4 in f) were used. Cells were stimulated with 977 
2μg/ml of individual or pooled peptides or 20μg/ml PPD, or left unstimulated, with 3X105 cells 978 
per well in duplicates. Cells were stimulated with a fbpA44-51 FSRPGLPV, b BCG_3870c4-12 979 
LAASLLSRV, c fas57-65 GIETELATL, d iniC191-200 QIGGLVGGSV, e groL261-75 980 
LEDPYEKIGAELVKE and f a pool of peptides containing these five sequences and 981 
mmpL12396-403 AGCTLLIR and atpA333-340 KANDISAY (a peptide identified with a Peaks score 982 
of 14.54 hence excluded from the analysis). Each dot represents the results from each 983 
peptide. The error bars show the mean and standard errors of the mean. Statistical analysis 984 
performed with Two-tailed Mann-Whitney U test, and statistically significant differences 985 
between groups are represented as *p<0.05, **p<0.01.  986 
 987 
Fig. 4 Protective efficacy of selected antigens alone or in combination, against a challenge 988 
with an aerosol of M.tb Erdman. a Experimental design. All groups of CB6F1 mice were 989 
vaccinated with BCG, intradermally. Ten weeks later, mice were boosted with intranasal 990 
ChAdOx1, followed by intradermal MVA, four weeks later, the BCM schedule. A group of 991 
mice was vaccinated with BCG only and another group left unvaccinated. Four weeks after 992 
BCM, all mice were challenged with an aerosol of M.tb Erdman (100 CFU per animal). Four 993 
weeks later, animals were culled, lung and spleen harvested and CFU counted. CFU from 994 
lung (b) and spleen (c), from the first experiment comprising of BCM expressing single 995 
antigens (glfT2, fas, iniB or Ag85A). CFU from lung (d) and spleen (e), from the second 996 
experiment consisting of BCM expressing single antigens (glfT2, fas, or iniB) or a 997 
combination of these three antigens (GIF) or a combination of GIF plus Ag85A and PPE15 998 
(GIFPA). CFU, colony forming units, n=8. Each symbol represents one animal, the error bars 999 
represent the median and the columns represent the interquartile range. Kruskal-Wallis 1000 
followed by Dunn’s multiple comparison test (black bars) as well as Mann-Whitney U test 1001 
(grey bars) were used to assess significance, *p<0.05, **p<0.01.  1002 
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Antigens selected  Identification 
Symbol Name  Exp. Presented Refs. 
BCG_3870c 
 (glfT2) 
Galactofuranosyl 
transferase 
 1  MHC-I This study and  
Flyer et al 
(2002) 
fas Probable fatty acid  
synthase fas 
 2, 3 MHC-I and -II This study 
iniB Isoniazid inductible 
gene protein iniB 
 N/I N/A Flyer et al 
(2002) 
McMurtrey et al 
(2017) 
PPE15 PPE family protein 
PPE15 
 N/I N/A Stylianou et al 
(2018) 
fbpA  
(Ag85A) 
Diacylglycerol 
acyltransferase/ 
mycolyltransferase 
Ag85A 
 3, 4 MHC-I This study and  
Stylianou et al 
(2015) 
N/I – Not identified in this study. 
N/A – Not available. 
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MHC-II 
MHC-I 71 
5 
36 
b 
d 
e f 
82 Unique peptides 
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43 
False Positive Removal 
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74 20 
68 3 6 17 
 23,976 All unique peptides 17,765 
35 8 
29 3 6 5 
Frequency 
I 
IX VII V III 
II 
X VIII VI IV 
 23,894 17,599 
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